Literature DB >> 2775697

Neutrophil activation in pregnancy-induced hypertension.

I A Greer1, N G Haddad, J Dawes, F D Johnstone, A A Calder.   

Abstract

Human neutrophil elastase may be a major mediator of vascular damage and could contribute to the vascular damage seen in women with pregnancy-induced hypertension (PIH). Elevated plasma levels of this substance will reflect neutrophil activation in vivo. To determine neutrophil activation in PIH, we studied 30 normal non-pregnant women, 32 women with normal pregnancies, 19 with mild/moderate PIH and 16 with severe PIH between 28 and 39 weeks gestation. Plasma neutrophil elastase was measured by radioimmunoassay. There was a significantly higher concentration of plasma neutrophil elastase in both mild/moderate and severe PIH than in normotensive pregnancies and this may contribute to the vascular lesion associated with PIH. Concentrations were also significantly higher in normal pregnancy than in non-pregnant women which suggests that neutrophil activation and degranulation are increased in normal pregnancy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2775697     DOI: 10.1111/j.1471-0528.1989.tb03358.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  23 in total

1.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

2.  Cardiac myeloperoxidase activity is elevated in hypertensive pregnant rats.

Authors:  Ming-Lin Zhu; Jin-Ping Zhao; Ning Cui; Victor H Gonçalves-Rizzi; Jose S Possomato-Vieira; Regina A Nascimento; Carlos A Dias-Junior
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

3.  Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1.

Authors:  William H Nugent; Nikita Mishra; Jerome F Strauss; Scott W Walsh
Journal:  Reprod Sci       Date:  2015-10-04       Impact factor: 3.060

4.  Increased expression of matrix metalloproteinase-1 in systemic vessels of preeclamptic women: a critical mediator of vascular dysfunction.

Authors:  Guadalupe Estrada-Gutierrez; Renato E Cappello; Nikita Mishra; Roberto Romero; Jerome F Strauss; Scott W Walsh
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

5.  Neutrophil expression of cyclooxygenase 2 in preeclampsia.

Authors:  Teddi Bachawaty; Sonya L Washington; Scott W Walsh
Journal:  Reprod Sci       Date:  2010-03-10       Impact factor: 3.060

6.  Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products.

Authors:  Eleazar Soto; Roberto Romero; Karina Richani; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Jyh Kae Nien; Sam S Edwin; Yeon Mee Kim; Joon Seok Hong; Luis F Goncalves; Lami Yeo; Moshe Mazor; Sonia S Hassan; Juan Pedro Kusanovic
Journal:  J Matern Fetal Neonatal Med       Date:  2010-07

7.  Elevated maternal IL-16 levels, enhanced IL-16 expressions in endothelium and leukocytes, and increased IL-16 production by placental trophoblasts in women with preeclampsia.

Authors:  Yang Gu; David F Lewis; Kelli Deere; Lynn J Groome; Yuping Wang
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  Plasma from preeclamptic women stimulates transendothelial migration of neutrophils.

Authors:  Scott W Walsh
Journal:  Reprod Sci       Date:  2008-12-15       Impact factor: 3.060

9.  Increased neutrophil numbers account for leukocytosis in women with preeclampsia.

Authors:  Bernard J Canzoneri; David F Lewis; Lynn Groome; Yuping Wang
Journal:  Am J Perinatol       Date:  2009-05-18       Impact factor: 1.862

10.  Increased myeloperoxidase in the placenta and circulation of women with preeclampsia.

Authors:  Robin E Gandley; Jennifer Rohland; Yan Zhou; Eiji Shibata; Gail F Harger; Augustine Rajakumar; Valerian E Kagan; Nina Markovic; Carl A Hubel
Journal:  Hypertension       Date:  2008-06-30       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.